Novartis subsidiary Sandoz's antibiotics efforts bear fruit during pandemic

Sandoz stands out from other pharmaceutical companies, as it produces both the active ingredients for antibiotics and the finished product. This is a strategy that served the company well during the pandemic, says Chief Business Officer Carol Lynch.

Photo: Sandoz / PR

The pandemic has been a blessing and a curse for Sandoz's antibiotics business.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs